Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Current Assets (2016 - 2025)

Aptevo Therapeutics' Current Assets history spans 11 years, with the latest figure at $22.6 million for Q3 2025.

  • For Q3 2025, Current Assets rose 126.22% year-over-year to $22.6 million; the TTM value through Sep 2025 reached $22.6 million, up 126.22%, while the annual FY2024 figure was $10.7 million, 44.09% down from the prior year.
  • Current Assets for Q3 2025 was $22.6 million at Aptevo Therapeutics, up from $11.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $65.8 million in Q2 2021 and bottomed at $3.6 million in Q1 2025.
  • The 5-year median for Current Assets is $22.7 million (2023), against an average of $28.2 million.
  • The largest annual shift saw Current Assets surged 527.05% in 2021 before it crashed 70.13% in 2025.
  • A 5-year view of Current Assets shows it stood at $52.6 million in 2021, then tumbled by 47.78% to $27.4 million in 2022, then plummeted by 30.54% to $19.1 million in 2023, then plummeted by 44.09% to $10.7 million in 2024, then surged by 112.49% to $22.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Current Assets are $22.6 million (Q3 2025), $11.1 million (Q2 2025), and $3.6 million (Q1 2025).